Vitrakvi is a prescription medication that is used to treat adults and children with solid tumors.
The pharmaceutical agent is designed to treat tumors that are caused by certain abnormal NTRK genes, have spread or if surgery to remove their cancer is likely to cause severe complications, there is no acceptable treatment option or cancer grew or spread on another treatment.
Bayer said the drug was approved through a faster FDA review process based on the percentage of patients whose tumor size shrank or disappeared after treatment and how long the response lasted.
Common side effects associated with Vitrakvi include tiredness, cough, nausea, constipation, dizziness, diarrhea and vomiting.
Filed Under: Drug Discovery, Drug Discovery and Development, Neurological Disease, Oncology, Orphan Drugs